Portfolio
Business development opportunities

EUSA Pharma is seeking to in-license oncology, pain control and critical care products currently in phase III for its target markets in Europe and North America in the following areas – Oncology, Pain and Critical Care.  

In addition, EUSA is divesting a series of development programs that are outside its strategic focus. The first includes three CNS
pre-clinical compounds: TKP1001 for Alzheimer’s disease, TKP1002 for Schizophrenia and
3,4 DAP for fatigue in MS.
See the Pipeline.

All Business development opportunities should be directed to Simon Ball, Business Development Director: simon.ball@eusapharma.com